Sunshine Biopharma Inc. (SBFM): Price and Financial Metrics
GET POWR RATINGS... FREE!
SBFM Stock Price Chart Interactive Chart >
SBFM Price/Volume Stats
|Current price||$0.77||52-week high||$15.60|
|Prev. close||$0.79||52-week low||$0.62|
|Day high||$0.80||Avg. volume||3,675,301|
|50-day MA||$0.83||Dividend yield||N/A|
|200-day MA||$1.66||Market Cap||17.50M|
Sunshine Biopharma Inc. (SBFM) Company Bio
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. Its products include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.
Most Popular Stories View All
SBFM Latest News Stream
|Loading, please wait...|
SBFM Latest Social Stream
View Full SBFM Social Stream
Latest SBFM News From Around the Web
Below are the latest news stories about SUNSHINE BIOPHARMA INC that investors may wish to consider to help them evaluate SBFM as an investment opportunity.
Christine Petraglia - TraDigital IR
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
Sunshine Biopharma Inc (NASDAQ: SBFM) has entered into a collaboration agreement with a North American lipid nanoparticle (LNP) company to advance the development of its mRNA-based anticancer macromolecule, K1.1. The company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma previously showed that its K1.1 mRNA could destroy cancer cells in vitro, including multidrug-resistant breast
Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (“LNP”) companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1. Th
Sunshine Biopharma Third Quarter 2022 Earnings: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)
Sunshine Biopharma ( NASDAQ:SBFM ) Third Quarter 2022 Results Key Financial Results Net loss: US$1.46m (loss narrowed...
SBFM Price Returns